{
    "clinical_study": {
        "@rank": "62051", 
        "arm_group": [
            {
                "arm_group_label": "Miravirsen every other week dosing", 
                "arm_group_type": "Other", 
                "description": "Miravirsen will be dosed as single subcutaneous injections.  Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin."
            }, 
            {
                "arm_group_label": "Miravirsen monthly dosing", 
                "arm_group_type": "Other", 
                "description": "Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this open-label study is to assess the safety, tolerability, antiviral\n      activity, genotype resistance associated with virological failure, pharmacokinetics and\n      pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and\n      ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to\n      pegylated-interferon alpha and ribavirin."
        }, 
        "brief_title": "Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of chronic hepatitis C genotype 1 infection\n\n          -  BMI 18 and 38 kg/m2\n\n          -  Null responder to pegylated interferon alpha and ribavirin\n\n        Exclusion Criteria:\n\n          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\n          -  Significant liver disease in addition to hepatitis C\n\n          -  Decompensated liver disease medical  history or current  clinical features\n\n          -  Histologic evidence of hepatic cirrhosis\n\n          -  Concurrent clinically significant medical  diagnosis (other than CHC)\n\n          -  Concurrent social conditions (e.g. drugs  of abuse, alcohol excess, poor living\n             accommodation)\n\n          -  Clinically significant illness within 30 days  preceding entry into the study\n\n          -  Participated in an investigational drug study within 30 days  or 5 half-lives,\n             whichever is longer, prior to the start of study medication\n\n          -  History of clinically significant allergic drug reactions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872936", 
            "org_study_id": "SPC3649-205"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Miravirsen every other week dosing", 
                    "Miravirsen monthly dosing"
                ], 
                "intervention_name": "Miravirsen", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SPC3649", 
                    "Miravirsen sodium"
                ]
            }, 
            {
                "arm_group_label": [
                    "Miravirsen every other week dosing", 
                    "Miravirsen monthly dosing"
                ], 
                "intervention_name": "Telaprevir", 
                "intervention_type": "Drug", 
                "other_name": "Incivek"
            }, 
            {
                "arm_group_label": [
                    "Miravirsen every other week dosing", 
                    "Miravirsen monthly dosing"
                ], 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Copegus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75203"
                    }, 
                    "name": "The Liver Institute at Methodist Dallas Medical Center"
                }, 
                "investigator": {
                    "last_name": "Parvez S Mantry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Research Specialists of Texas"
                }, 
                "investigator": {
                    "last_name": "Joseph S Galati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Fundacion de Investigacion de Diego"
                }, 
                "investigator": {
                    "last_name": "Maribel Rodriguez-Torres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection", 
        "other_outcome": [
            {
                "description": "The miR-122 seed sites  in HCV RNA from subjects at baseline and following viral breakthrough or relapse will be subjected to genotypic sequence analysis.", 
                "measure": "Viral resistance analysis at baseline and throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "66 Weeks"
            }, 
            {
                "description": "A single sample will be collected at select study visits for all subjects through Week 31.  A subset of subjects will participate in extended PK sampling for up to 5 hours at select study visits and for up to 24 hours after the last dose of miravirsen.", 
                "measure": "Plasma pharmacokinetics (AUC, Cmax, tmax) for miravirsen, telaprevir, and ribavirin levels will be determined.", 
                "safety_issue": "No", 
                "time_frame": "31 Weeks"
            }, 
            {
                "description": "Urine pharmacokinetics (AUC, Cmax, tmax) for miravirsen levels will be measured in a subset of subjects for up to 24 hours after the last dose of miravirsen.", 
                "measure": "Urine pharmacokinetics for miravirsen levels will be determined.", 
                "safety_issue": "No", 
                "time_frame": "Up to 16 Weeks"
            }
        ], 
        "overall_contact": {
            "email": "cc@santaris.com", 
            "last_name": "Constance Crowley"
        }, 
        "overall_official": {
            "affiliation": "Santaris Pharma A/S", 
            "last_name": "Michael Hodges, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects with a Sustained Virological Response at 24 weeks after the end of therapy.", 
            "safety_issue": "No", 
            "time_frame": "42 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872936"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects with undetectable HCV RNA levels at end of treatment.", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "The proportion of subjects with a Sustained Virological Response at 12 and 48 weeks after the end of therapy.", 
                "safety_issue": "No", 
                "time_frame": "66 Weeks"
            }, 
            {
                "measure": "Change in HCV RNA levels from baseline throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "66 Weeks"
            }, 
            {
                "measure": "The proportion of subjects who experience virological failure throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "66 Weeks"
            }
        ], 
        "source": "Santaris Pharma A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santaris Pharma A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}